Go Pro

Veru (VERU) Competitors

Veru logo
$3.06 0.00 (0.00%)
Closing price 07/2/2026 04:00 PM Eastern
Extended Trading
$3.00 -0.06 (-2.09%)
As of 07/2/2026 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

VERU vs. MED, EL, IPAR, PBH, and HLF

Should you buy Veru stock or one of its competitors? MarketBeat compares Veru with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Veru include Medifast (MED), Estee Lauder Companies (EL), Interparfums (IPAR), Prestige Consumer Healthcare (PBH), and Herbalife (HLF). These companies are all part of the "personal products" industry.

How does Veru compare to Medifast?

Medifast (NYSE:MED) and Veru (NASDAQ:VERU) are both small-cap personal products companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings.

95.5% of Medifast shares are owned by institutional investors. Comparatively, 47.2% of Veru shares are owned by institutional investors. 3.7% of Medifast shares are owned by insiders. Comparatively, 14.2% of Veru shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Medifast has a beta of 0.65, meaning that its share price is 35% less volatile than the broader market. Comparatively, Veru has a beta of -1.19, meaning that its share price is 219% less volatile than the broader market.

In the previous week, Veru had 1 more articles in the media than Medifast. MarketBeat recorded 1 mentions for Veru and 0 mentions for Medifast. Veru's average media sentiment score of 1.05 beat Medifast's score of 0.00 indicating that Veru is being referred to more favorably in the news media.

Company Overall Sentiment
Medifast Neutral
Veru Positive

Medifast presently has a consensus target price of $12.00, indicating a potential upside of 9.14%. Veru has a consensus target price of $23.00, indicating a potential upside of 651.63%. Given Veru's stronger consensus rating and higher possible upside, analysts plainly believe Veru is more favorable than Medifast.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Medifast
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50
Veru
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

Medifast has higher revenue and earnings than Veru. Medifast is trading at a lower price-to-earnings ratio than Veru, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medifast$385.79M0.32-$18.67M-$1.83N/A
Veru$16.89M2.91-$22.73M-$0.89N/A

Veru has a net margin of 0.00% compared to Medifast's net margin of -5.78%. Medifast's return on equity of -4.80% beat Veru's return on equity.

Company Net Margins Return on Equity Return on Assets
Medifast-5.78% -4.80% -3.83%
Veru N/A -54.72%-39.09%

Summary

Veru beats Medifast on 10 of the 16 factors compared between the two stocks.

How does Veru compare to Estee Lauder Companies?

Estee Lauder Companies (NYSE:EL) and Veru (NASDAQ:VERU) are both personal products companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.

Veru has a net margin of 0.00% compared to Estee Lauder Companies' net margin of -1.67%. Estee Lauder Companies' return on equity of 20.66% beat Veru's return on equity.

Company Net Margins Return on Equity Return on Assets
Estee Lauder Companies-1.67% 20.66% 4.15%
Veru N/A -54.72%-39.09%

Estee Lauder Companies currently has a consensus target price of $99.90, indicating a potential upside of 19.16%. Veru has a consensus target price of $23.00, indicating a potential upside of 651.63%. Given Veru's higher probable upside, analysts clearly believe Veru is more favorable than Estee Lauder Companies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Estee Lauder Companies
2 Sell rating(s)
9 Hold rating(s)
9 Buy rating(s)
2 Strong Buy rating(s)
2.50
Veru
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

55.2% of Estee Lauder Companies shares are owned by institutional investors. Comparatively, 47.2% of Veru shares are owned by institutional investors. 13.1% of Estee Lauder Companies shares are owned by insiders. Comparatively, 14.2% of Veru shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Estee Lauder Companies has a beta of 1.27, indicating that its stock price is 27% more volatile than the broader market. Comparatively, Veru has a beta of -1.19, indicating that its stock price is 219% less volatile than the broader market.

Veru has lower revenue, but higher earnings than Estee Lauder Companies. Estee Lauder Companies is trading at a lower price-to-earnings ratio than Veru, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Estee Lauder Companies$14.33B2.12-$1.13B-$0.70N/A
Veru$16.89M2.91-$22.73M-$0.89N/A

In the previous week, Estee Lauder Companies had 9 more articles in the media than Veru. MarketBeat recorded 10 mentions for Estee Lauder Companies and 1 mentions for Veru. Veru's average media sentiment score of 1.05 beat Estee Lauder Companies' score of 0.93 indicating that Veru is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Estee Lauder Companies
6 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive
Veru
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Estee Lauder Companies beats Veru on 9 of the 16 factors compared between the two stocks.

How does Veru compare to Interparfums?

Interparfums (NASDAQ:IPAR) and Veru (NASDAQ:VERU) are both personal products companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, analyst recommendations, media sentiment, earnings, dividends and profitability.

55.6% of Interparfums shares are held by institutional investors. Comparatively, 47.2% of Veru shares are held by institutional investors. 43.7% of Interparfums shares are held by insiders. Comparatively, 14.2% of Veru shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Interparfums presently has a consensus target price of $106.00, suggesting a potential downside of 11.22%. Veru has a consensus target price of $23.00, suggesting a potential upside of 651.63%. Given Veru's higher probable upside, analysts clearly believe Veru is more favorable than Interparfums.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Interparfums
0 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.75
Veru
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

Interparfums has higher revenue and earnings than Veru. Veru is trading at a lower price-to-earnings ratio than Interparfums, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Interparfums$1.49B2.57$168.39M$5.2722.65
Veru$16.89M2.91-$22.73M-$0.89N/A

In the previous week, Interparfums had 1 more articles in the media than Veru. MarketBeat recorded 2 mentions for Interparfums and 1 mentions for Veru. Veru's average media sentiment score of 1.05 beat Interparfums' score of 0.50 indicating that Veru is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Interparfums
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Veru
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Interparfums has a net margin of 11.32% compared to Veru's net margin of 0.00%. Interparfums' return on equity of 15.47% beat Veru's return on equity.

Company Net Margins Return on Equity Return on Assets
Interparfums11.32% 15.47% 10.82%
Veru N/A -54.72%-39.09%

Interparfums has a beta of 1.13, indicating that its share price is 13% more volatile than the broader market. Comparatively, Veru has a beta of -1.19, indicating that its share price is 219% less volatile than the broader market.

Summary

Interparfums beats Veru on 14 of the 17 factors compared between the two stocks.

How does Veru compare to Prestige Consumer Healthcare?

Veru (NASDAQ:VERU) and Prestige Consumer Healthcare (NYSE:PBH) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, media sentiment, profitability, earnings and risk.

Veru presently has a consensus target price of $23.00, suggesting a potential upside of 651.63%. Prestige Consumer Healthcare has a consensus target price of $70.75, suggesting a potential upside of 43.27%. Given Veru's stronger consensus rating and higher possible upside, equities research analysts plainly believe Veru is more favorable than Prestige Consumer Healthcare.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Veru
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
Prestige Consumer Healthcare
2 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.00

Prestige Consumer Healthcare has higher revenue and earnings than Veru. Veru is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Veru$16.89M2.91-$22.73M-$0.89N/A
Prestige Consumer Healthcare$1.09B2.15$190.30M$3.9112.63

Prestige Consumer Healthcare has a net margin of 17.48% compared to Veru's net margin of 0.00%. Prestige Consumer Healthcare's return on equity of 11.54% beat Veru's return on equity.

Company Net Margins Return on Equity Return on Assets
VeruN/A -54.72% -39.09%
Prestige Consumer Healthcare 17.48%11.54%6.16%

47.2% of Veru shares are held by institutional investors. Comparatively, 100.0% of Prestige Consumer Healthcare shares are held by institutional investors. 14.2% of Veru shares are held by company insiders. Comparatively, 1.5% of Prestige Consumer Healthcare shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Veru has a beta of -1.19, suggesting that its share price is 219% less volatile than the broader market. Comparatively, Prestige Consumer Healthcare has a beta of 0.35, suggesting that its share price is 65% less volatile than the broader market.

In the previous week, Prestige Consumer Healthcare had 5 more articles in the media than Veru. MarketBeat recorded 6 mentions for Prestige Consumer Healthcare and 1 mentions for Veru. Prestige Consumer Healthcare's average media sentiment score of 1.50 beat Veru's score of 1.05 indicating that Prestige Consumer Healthcare is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Veru
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Prestige Consumer Healthcare
4 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

Summary

Prestige Consumer Healthcare beats Veru on 11 of the 16 factors compared between the two stocks.

How does Veru compare to Herbalife?

Herbalife (NYSE:HLF) and Veru (NASDAQ:VERU) are both small-cap personal products companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings, media sentiment and analyst recommendations.

Herbalife has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market. Comparatively, Veru has a beta of -1.19, indicating that its stock price is 219% less volatile than the broader market.

Herbalife has higher revenue and earnings than Veru. Veru is trading at a lower price-to-earnings ratio than Herbalife, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Herbalife$5.04B0.27$228.30M$2.285.76
Veru$16.89M2.91-$22.73M-$0.89N/A

Herbalife has a net margin of 4.67% compared to Veru's net margin of 0.00%. Herbalife's return on equity of -41.47% beat Veru's return on equity.

Company Net Margins Return on Equity Return on Assets
Herbalife4.67% -41.47% 8.24%
Veru N/A -54.72%-39.09%

47.2% of Veru shares are owned by institutional investors. 5.1% of Herbalife shares are owned by company insiders. Comparatively, 14.2% of Veru shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Herbalife had 3 more articles in the media than Veru. MarketBeat recorded 4 mentions for Herbalife and 1 mentions for Veru. Veru's average media sentiment score of 1.05 beat Herbalife's score of 0.22 indicating that Veru is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Herbalife
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
Veru
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Herbalife currently has a consensus price target of $17.80, suggesting a potential upside of 35.52%. Veru has a consensus price target of $23.00, suggesting a potential upside of 651.63%. Given Veru's stronger consensus rating and higher probable upside, analysts clearly believe Veru is more favorable than Herbalife.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Herbalife
0 Sell rating(s)
4 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.43
Veru
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

Summary

Herbalife beats Veru on 9 of the 15 factors compared between the two stocks.

Get Veru News Delivered to You Automatically

Sign up to receive the latest news and ratings for VERU and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VERU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VERU vs. The Competition

MetricVeruMED PRODUCTS IndustryMedical SectorNASDAQ Exchange
Market Cap$49.11M$8.77B$7.18B$12.47B
Dividend YieldN/A2.45%2.67%6.51%
P/E Ratio-3.4416.5528.0224.70
Price / Sales2.917.46534.8299.69
Price / CashN/A18.1149.2657.09
Price / Book2.453.5310.966.46
Net Income-$22.73M$226.25M$3.57B$337.01M
7 Day Performance1.66%1.50%2.12%1.69%
1 Month Performance-10.00%-0.23%5.25%3.81%
1 Year Performance-49.00%-0.49%33.29%23.90%

Veru Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VERU
Veru
2.9422 of 5 stars
$3.06
flat
$23.00
+651.6%
-49.0%$49.11M$16.89MN/A230
MED
Medifast
1.4112 of 5 stars
$11.07
+0.3%
$12.00
+8.4%
-24.6%$122.75M$385.79MN/A870
EL
Estee Lauder Companies
4.7406 of 5 stars
$84.64
-0.2%
$99.90
+18.0%
-5.4%$30.68B$14.83BN/A57,000
IPAR
Interparfums
2.5948 of 5 stars
$97.75
-1.4%
$106.00
+8.4%
-13.8%$3.17B$1.49B18.55530
PBH
Prestige Consumer Healthcare
4.0932 of 5 stars
$45.47
-3.2%
$70.75
+55.6%
-38.3%$2.23B$1.09B11.63540

Related Companies and Tools


This page (NASDAQ:VERU) was last updated on 7/5/2026 by MarketBeat.com Staff.
From Our Partners